Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kura Oncology Inc KURA

Healthcare Biotechnology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that... see more

Recent & Breaking News (NDAQ:KURA)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURA

Newsfile November 28, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURA

PR Newswire November 25, 2021

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

GlobeNewswire November 24, 2021

Kura Oncology to Participate in Two Upcoming Investor Conferences

GlobeNewswire November 23, 2021

Kura Oncology Reports Third Quarter 2021 Financial Results

GlobeNewswire November 4, 2021

Kura Oncology to Participate in Credit Suisse Healthcare Conference

GlobeNewswire November 2, 2021

Kura Oncology to Report Third Quarter 2021 Financial Results

GlobeNewswire October 28, 2021

Kura Oncology Appoints Teresa Bair as Chief Legal Officer

GlobeNewswire October 18, 2021

Kura Oncology to Participate in Two Upcoming Investor Conferences

GlobeNewswire September 7, 2021

Kura Oncology Reports Second Quarter 2021 Financial Results

GlobeNewswire August 5, 2021

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

GlobeNewswire August 4, 2021

Kura Oncology to Report Second Quarter 2021 Financial Results

GlobeNewswire July 29, 2021

Kura Oncology Appoints Helen Collins, M.D. to Board of Directors

GlobeNewswire July 29, 2021

Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

GlobeNewswire July 6, 2021

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

GlobeNewswire June 24, 2021

Kura Oncology to Participate in JMP Securities Life Sciences Conference

GlobeNewswire June 10, 2021

Kura Oncology Appoints Carol Schafer to Board of Directors

GlobeNewswire June 4, 2021

Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit

GlobeNewswire May 13, 2021

Kura Oncology Reports First Quarter 2021 Financial Results

GlobeNewswire May 6, 2021

Kura Oncology to Report First Quarter 2021 Financial Results

GlobeNewswire April 29, 2021